Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer's development partner Coley Pharmaceutical has initiated two phase III clinical studies of its investigational drug PF-3512676 in first-line non-small cell lung cancer under an FDA special protocol assessment procedure.
Subscribe to our email newsletter
In March 2005, Coley and Pfizer entered into an exclusive global license agreement to develop, manufacture and commercialize Coley’s PF-3512676, a Toll-like receptor 9 (TLR9) agonist delivered by subcutaneous injection, for the potential treatment and control of cancers in humans.
The phase III program, initiated under the direction of Pfizer, will evaluate PF-3512676 in combination with current standard-of- care chemotherapy regimens versus standard-of-care chemotherapy alone in the first-line treatment of patients with advanced non-small cell lung cancer.
The primary endpoint for the phase III clinical trials is overall survival. Each of the two phase III clinical trials will enroll approximately 800 adult patients with stage IIIb or IV disease.
Coley conducted a multi-center phase II clinical study of 112 patients in which results indicated the potential for a meaningful patient survival benefit among patients receiving PF-3512676 in combination with chemotherapy versus those who received chemotherapy alone for the first-line treatment of both of the major histologic subtypes of non-small cell lung cancer.